A carregar...
PCSK9 Inhibitors: An Emerging Class of Medications
Objective: To evaluate the safety and efficacy of 2 human monoclonal antibodies, alirocumab and evolocumab, on reduction of low-density lipoprotein cholesterol (LDL-C), cardiovascular benefits, and their place in current practice. Data Sources: A search of MEDLINE and Scopus databases (1966 to May 2...
Na minha lista:
| Publicado no: | J Pharm Technol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5998519/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/8755122516653970 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|